特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
951555

市場スポットライト:子宮筋腫

Market Spotlight: Uterine Fibroids

出版日: | 発行: Datamonitor Healthcare | ページ情報: 英文 38 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.60円
市場スポットライト:子宮筋腫
出版日: 2020年07月16日
発行: Datamonitor Healthcare
ページ情報: 英文 38 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の15歳以上の女性における子宮筋腫の有病者数は、2019年の約9,490万人から、2028年までに1億500万人まで増加すると予測されています。米国は、子宮筋腫の臨床試験数で、世界で先導しています。英国は、欧州の主要市場で主導しています。日本は、アジアで首位を占めています。

当レポートでは、世界の子宮筋腫治療薬市場について調査分析し、主な上市薬・パイプライン薬、臨床試験、最近の動向、将来の動向、成功確率、特許情報、10ヶ年予測などについて、体系的な情報を提供しています。

目次

概要

要点

疾患の背景

  • サブタイプ

治療

  • 手術
  • 医薬品

疫学

上市薬

パイプライン薬

最近の動向とアナリストの見解

近い将来の動向

主な規制の動向

成功確率

ライセンスと資産買収取引

親特許

収益機会

臨床試験情勢

  • スポンサー:ステータス別
  • スポンサー:フェーズ別

参考文献

  • 処方情報

付録

目次
Product Code: DMKC0183230

This Market Spotlight report covers the Uterine Fibroids market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming events, probability of success, regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were approximately 94.9 million prevalent cases of uterine fibroids worldwide in females aged 15 years and over, and forecasts that number to increase to 105.0 million prevalent cases by 2028.

Lupron, relugolix, and ORIAHNN, which target gonadotropin-releasing hormone receptor, and ulipristal acetate, which targets progesterone receptor, are the only approved drugs for uterine fibroids. These drugs are administered via the oral and subcutaneous routes.

The largest proportion of industry-sponsored drugs in active clinical development for uterine fibroids are in Phase III, with one drug in the NDA/BLA phase.

Therapies in development for uterine fibroids focus on targets such as progesterone receptor, gonadotropin-releasing hormone receptor, and collagen. The majority of pipeline drugs are administered via the oral route, with one product being available in a subcutaneous formulation.

High-impact upcoming events for drugs in the uterine fibroids space comprise topline Phase III trial results and an expected meeting with the FDA for linzagolix; and an estimated PDUFA date as well as an expected CHMP opinion for relugolix.

The overall likelihood of approval of a Phase I gynecology asset is 14.5%, and the average probability a drug advances from Phase III is 63.6%. Drugs, on average, take 11.8 years from Phase I to approval, compared to 13.0 years in the overall obstetrics/gynecology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for uterine fibroids have been in the early and mid-phases of development, with 59% of trials in Phase I-II, and 41% in Phase III-IV.

The US has a substantial lead in the number of uterine fibroids clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the uterine fibroids space is dominated by completed trials. Repros Therapeutics has the highest number of completed clinical trials for uterine fibroids, with 17 trials.

Repros Therapeutics leads industry sponsors with the highest number of clinical trials for uterine fibroids, followed by Takeda

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery
  • Medical agents

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Linzagolix for Uterine Fibroids (December 9, 2019)
  • Relugolix for Uterine Fibroids (July 23, 2019)
  • Multiple Drugs for Uterine Fibroids (June 25, 2019)
  • Relugolix for Uterine Fibroids (May 14, 2019)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Myovant's Relugolix Chases AbbVie's Elagolix In Women's Health Market
  • FDA Approves First Medical Treatment For Fibroid-Related Heavy Menstrual Bleeding
  • Myovant Sciences' Relugolix Among 14 New Hopefuls At EMA
  • Ulipristal Suspended In EU Pending Further Review
  • FDA Recommends Further Limiting Use Of Laparoscopic Power Morcellation
  • AbbVie Revs Up The Race To Market In Uterine Fibroids
  • Myovant Plans Q4 Uterine Fibroid Drug Filing In A Showdown With AbbVie

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Myovant Licenses Ex-US Relugolix Rights To Gedeon Richter
  • Deals Shaping The Medical Industry, August 2019
  • QXMedical Gets Exclusive Rights To University of Minnesota Bioresorbable Technology

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of uterine fibroids, 2019-28
  • Figure 2: Overview of pipeline drugs for uterine fibroids in the US
  • Figure 3: Pipeline drugs for uterine fibroids, by company
  • Figure 4: Pipeline drugs for uterine fibroids, by drug type
  • Figure 5: Pipeline drugs for uterine fibroids, by classification
  • Figure 6: Linzagolix for Uterine Fibroids (December 9, 2019): Phase III - PRIMROSE 2
  • Figure 7: Relugolix for Uterine Fibroids (July 23, 2019): Phase III - LIBERTY 2
  • Figure 8: Relugolix for Uterine Fibroids (May 14, 2019): Phase III - LIBERTY 1
  • Figure 9: Key upcoming events in uterine fibroids
  • Figure 10: Probability of success in the uterine fibroids pipeline
  • Figure 11: Clinical trials in uterine fibroids
  • Figure 12: Top 10 drugs for clinical trials in uterine fibroids
  • Figure 13: Top 10 companies for clinical trials in uterine fibroids
  • Figure 14: Trial locations in uterine fibroids
  • Figure 15: Uterine fibroids trials status
  • Figure 16: Uterine fibroids trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of uterine fibroids, 2019-28
  • Table 2: Marketed drugs for uterine fibroids
  • Table 3: Pipeline drugs for uterine fibroids in the US
  • Table 4: Linzagolix for Uterine Fibroids (December 9, 2019)
  • Table 5: Relugolix for Uterine Fibroids (July 23, 2019)
  • Table 6: Multiple Drugs for Uterine Fibroids (June 25, 2019)
  • Table 7: Relugolix for Uterine Fibroids (May 14, 2019)
  • Table 8: Historical global sales, by drug ($m), 2015-19
  • Table 9: Forecasted global sales, by drug ($m), 2020-24
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.